Online training botulinum toxin

Botulinum toxin online training for doctorsInterested?


Are you interested in an online training for doctors about botulinum toxin A or do you want to refresh your knowledge about botulinum toxin A?

For information material or to register please click here: www.smart-muskelkonzept.de


Botulinum toxin A (BoNT A) is the first-line therapy for focal spasticity.

We would like to introduce you to the diagnosis, management and treatment of spastic patients with botulinum toxin type A (BoNT-A) and introduce you to the SMART muscle concept.

With this simplified treatment concept, you can also carry out BoNT-A therapy in your practice with reduced complexity and benefit from many advantages, such as optimal planning and an expanded range of therapy options. The SMART muscle concept - simple for you, easier for your patients.

The Smart Muscle concept is designed to reduce complexity and thus enable you to immediately treat spastic patients pragmatically and yet very effectively with BoNT, even without any special prior knowledge.


How does the SMART muscle concept online training work?The training is divided into 3 modules:

I. Basics, II. Anatomy and III. Organizational.

Each module consists of smaller training units of approximately 10 to 15 minutes duration and is

Dr. med. Axel Schramm carried out the study.

The SMART training was certified by the Botulinum Toxin Working Group with a total of 4 credit points. After completing all modules, you can take a learning status check and then receive a certificate of successful participation.

For information material or to register please click here: www.smart-muskelkonzept.de

Oral antispastics should only be used if everyday spasticity (with impairments of passive and/or active functions) cannot be adequately controlled despite adequate physical and therapeutic measures (strong consensus). Indications for the use of oral antispastics are often more pronounced non-focal, multifocal, i.e. severe segmental spasticity in the sense of pronounced hemispasticity, paraspasticity as a form of segmental spasticity or generalized spasticity in the sense of tetraspasticity or shooting nocturnal spasms after a stroke or traumatic brain injury (strong consensus). In focal spasticity, focal drug injection treatment with botulinum toxin A (BoNT A) usually has a better benefit-risk ratio (see below) and should, where feasible, be used before the use of oral antispastics (strong consensus).

Video - Patient before and after treatment with botulinum toxin

Improvement of gait stability and reduction of the risk of falls by botulinum toxin type A in spastic-dystonic supinated-inverted equinus foot after stroke.

Source: Dr. med. Martin Schorl, Chief Physician of the Neurological Clinic at the Bad Wurzach Rehabilitation Clinic.

Indications for the use of abobotulinumtoxinA

AbobotulinumtoxinA is currently approved for the following indications:For the symptomatic treatment of focal spasticity:*

    of the upper extremities in adultsof the ankle in adult patients after stroke or traumatic brain injurywith dynamic equinus position of the lower extremities in ambulatory patients with infantile cerebral palsy from 2 years of age


For symptomatic treatment in adults:*

    For the symptomatic alternative treatment of idiopathic blepharospasm, hemifacial spasm and coexisting focal dystoniasFor the symptomatic treatment of cervical dystonia (torticollis spasmodicus) with onset in adulthood


Funding of the following service areas by the Bavarian Association of Statutory Health Insurance Physicians (KVB):Treatment of dystonia with botulinum toxinTreatment of dystonia with botulinum toxin: Pediatric and adolescent medical area: NeuropediatricsTreatment of spasmodic dysphonia with botulinum toxinTreatment of spasms and chronic migraines with botulinum toxinTreatment of spasms and chronic migraines with botulinum toxin: Pediatric and adolescent medical area: NeuropediatricsTreatment of excessive sweating with botulinum toxin


* The BoNT-A units are NOT interchangeable with the units of other BoNT-A preparations on the market

Effect profile of BoNT A between injection and reinjection

Schematic representation

Share by: